MMV (http://www.MMV.org) and
The WHO’s Guidelines for the Treatment of Malaria are the standard reference which guide country-level policies for managing malaria. New medicines are only recommended for inclusion following a robust and in-depth evaluation of evidence using the GRADE (http://bit.ly/3XuGnSy) framework, which provides a systematic approach for making clinical practice recommendations. Following this review — which included one of the largest clinical studies to evaluate real-world efficacy and safety of any antimalarial — the Guideline Development Committee recommended the formal inclusion of Pyramax in the guidelines with a "STRONG" recommendation — the highest level of confidence.
Pyramax is a fixed dose artemisinin-based combination therapy (ACT) and the only one to be specifically indicated for the blood-stage treatment of the two dominant species of malaria parasite: P. falciparum and P. vivax. The medicine is also available in a child-friendly granule formulation to ensure palatability and therefore correct dosage in this vulnerable population.
Both Pyramax tablets and Pyramax granules received
Both formulations are currently registered for the treatment of uncomplicated malaria in 29 countries in
Following the positive scientific opinions for use, a large Cohort Event Monitoring study was implemented in 5 African countries [1]under the supervision of the CANTAM Network [2]to evaluate the safety and effectiveness of Pyramax under conditions similar to everyday clinical practice. This study, which reported high effectiveness (D28 PCR-adjusted cure rate of 98.6%), included over 8,500 acute malaria episodes in 7,154 patients, and has recently been published in PLoS Medicine [3].
Pyramax was included in the WHO’s list of pre-qualified medicines in 2012, and in the WHO’s Essential Medicines Lists for both adults and children in 2017. Pyramax has subsequently undergone a positive review by the WHO’s
Following this review in
"The addition of Pyramax to the
"The official inclusion of Pyramax into WHO’s Guidelines for malaria is a crucial step allowing malaria endemic countries to choose Pyramax as a first line ACT with confidence. The managerial decision to commence the Pyramax project was based on Shin Poong’s core values and company policies, which have guided us for over half a century. We will continue to produce qualified products to supply potent, reliable, simple treatment to patients", said
[1]
[2] For more information about CANTAM, please visit: http://bit.ly/3GGf9CE
[3] To read the CANTAM study, please visit: http://bit.ly/3u4n6tD
Distributed by
For more information:
Director of Communications, MMV
Phone +41 79 709 59 92
E-mail: polle@mmv.org
Akolade Omishope
Associate Director of Communications, MMV
Phone +41 79 896 20 61
E-mail: omishopea@mmv.org
Background on the malaria burden
According to the latest World Malaria Report (http://bit.ly/3EIJPRg), released on
In 2020, six countries accounted for just over half of all malaria deaths worldwide:
About Pyramax®
Pyramax, a fixed-dose combination of pyronaridine and artesunate and the newest ACT combination to be approved by a
This once-daily, 3-day therapy is indicated for the treatment of acute uncomplicated malaria in adults and children over 20 kg (Pyramax® tablets) and in children and infants between 5 and 20 kg (Pyramax® granules).
About Article 58
Article 58 of Regulation (EC) No 726/2004 establishes a mechanism whereby the
Article 58 of the Regulation responds to the need to protect and promote public health and to give scientific assistance to non-EU countries in the context of cooperation with
About
Shin Poong was founded in 1962 with headquarters based in
‘For the health of the people’ is the driven corporate philosophy of the Company. Shin Poong contributed largely to eradicate parasitic diseases from
Shin Poong with its partners were pioneers in Public Development Partnership’ access providing a healthcare model to end global epidemics of infectious diseases and to work for end-to-end execution from early discovery to field implementation for endemic infections.
For more information, please visit http://bit.ly/3OOIY6d
About
MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.
MMV receives funding and support from government agencies, private foundations, international organizations, corporations, corporate foundations and private individuals. These funds are used to finance MMV’s portfolio of R&D projects, as well as specific, targeted access & product management (APM) interventions that aim to facilitate increased access to malaria medicines by vulnerable populations in disease-endemic countries and support their appropriate use.
Since its foundation in 1999, MMV and partners have built the largest portfolio of antimalarial R&D and access projects ever assembled and have brought forward 15 new medicines. Almost 3 million lives have been saved by these MMV co-developed medicines. MMV's success is based on its extensive partnership network of around 150 active partners including from the pharmaceutical industry, academia and endemic countries.
MMV's vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease.
For more information, visit http://www.MMV.org
MMV Disclaimer
This document contains certain forward-looking statements that may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions, or by discussion of, among other things, vision, strategy, goals, plans, or intentions. It contains hypothetical future product target profiles, development timelines and approval/launch dates, positioning statements, claims and actions for which the relevant data may still have to be established. Stated or implied strategies and action items may be implemented only upon receipt of approvals including, but not limited to, local institutional review board approvals, local regulatory approvals, and following local laws and regulations. Thus, actual results, performances or events may differ from those expressed or implied by such statements.
We ask you not rely unduly on these statements. Such forward-looking statements reflect the current views of
MMV accepts no liability for the information presented here, nor for the consequences of any actions taken on the basis of this information. Furthermore, MMV accepts no liability for the decisions made by its pharmaceutical partner(s), the impact of any of their decisions, their earnings and their financial status.
© African Press Organization, source